Talzenna
Adding Talazoparib to Enzalutamide in mCRPC Improves Outcomes
In patients with metastatic, castration-resistant prostate cancer, adding the PARP inhibitor talazoparib (Talzenna, ...
MARCH 10, 2023
FDA Approves Talzenna for gBRCAm HER2– Breast Ca
The FDA approved Talzenna, a poly(adenosine diphosphate–ribose) polymerase inhibitor, for patients with ...
OCTOBER 18, 2018
Load more